ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Case Report

Systemic lupus erythematosus and Hodgkin disease

[version 1; peer review: 1 approved, 1 approved with reservations]
PUBLISHED 18 Oct 2012
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

Abstract

We report on the rare association of Hodgkin’s disease with systemic lupus erythematosus. Four years after the diagnosis of systemic lupus erythematosus, the patient developed cervical mass and weight loss. Histological and subsequent clonality studies confirmed classical Hodgkin’s lymphoma. The awareness of the association of Hodgkin’s disease with systemic lupus erythematosus and its modes of presentation will help in the early diagnosis and management of such patients.

Introduction

Systemic lupus erythematosus (SLE) is associated with lymphoproliferative diseases such as Hodgkin’s lymphoma (HL)1. Since there is considerable overlap between the features of SLE and HL there can be a great difficulty in diagnosing HL in the presence of SLE1.

Case report

A 35-year-old woman was followed from 2002 for SLE with neuropsychiatric, renal and hematologic involvements. She was treated with only glucocorticoids with favourable outcomes. In April 2006, when she was under steroid treatment of 10 mg/day, she was admitted for cervical mass and weight loss. Physical examination showed a left indolent, fixed and elastic cervical adenopathy. The biological assessment was normal. Computerized tomography of the chest and abdomen showed a left basicervical mass expanded to the anterior and superior mediastinum. Magnetic resonance imaging was suggestive of a thymoma (Figure 1, Figure 2). The cervicotomy showed a supraclavicular mass. Histological and subsequent clonality studies confirmed classical Hodgkin’s lymphoma (HL) of the nodular sclerosing type. Viral serology (for Epstein-Barr, herpes simplex, and herpes zoster) was negative. The diagnosis of Hodgkin’s disease stage Ia was retained and the patient was transferred to hematological department where she was treated by chemotherapy (adriamycin, bleomycin, vinblastine and dacarbazine) with favourable outcomes. She is being currently followed in our department and is in remission of her lupus and Hodgkin's disease.

240a86f9-cca0-48f9-a9c6-7b80ed194f06_figure1.gif

Figure 1. MRI thoracic sagittal suggestive of a thymoma.

240a86f9-cca0-48f9-a9c6-7b80ed194f06_figure2.gif

Figure 2. MRI thoracic coronal suggestive of a thymoma.

Discussion

The relative risk of hematologic malignancy is estimated to be 60% higher in patients with SLE than in the general population, the reason being unknown1. Of all hematologic cases reported in patients with SLE, the most common is non-Hodgkin’s lymphoma followed by Hodgkin’s disease, leukemia, and then multiple myeloma1.

The initial presenting features of SLE and Hodgkin’s disease are similar, with fever, weight loss, and peripheral lymphadenopathy seen in most cases1. Our patient presented with weight loss and cervical adenopathy.

Persistent large lymph nodes not responding to conventional therapy in SLE should be biopsied for alternative diagnosis (i.e., lymphoma)1.

Several conditions and links have been identified that could potentially predispose patients with SLE to cancer (Table 1)2,3.

Table 1. Potential links between systemic lupus erythematosus and malignancy.

* Growth and hormonal factors may play a role in autoimmunity as well as in malignancy3.

▪   Similarities between SLE immunologic disturbances and B-cell malignancies

         ○  Abnormalities in survival, proliferation, and differentiation of lymphocytes

         ○  Similar defects in apoptosis

         ○  Chronic antigenic stimulation (can lead to lupus-like autoimmunity and B-cell
              lymphomas in mice models of graft-versus-host disease)

▪   Growth and hormonal factors*

         ○  Insulin-like growth factor

         ○  Prolactin

         ○  Growth hormone

▪   Viral triggers

         ○  Epstein-Barr virus

▪   Other.

         ○  Secondary Sjögren syndrome

         ○  Exposure to cytotoxic and immunomodulatory drugs used to manage SLE

         ○  Increased prevalence of traditional risk factors for malignancies (e.g., nulliparity,
              obesity) in patients with SLE

A side-effect of immunosuppression is a possibility, as is intercurrent viral infection due to, for example, Epstein-Barr, herpes simplex, herpes zoster and polyoma viruses, which are potentially oncogenic. In our case, viral serology was negative.

Patients who have had a renal transplant are known to have an increased risk of cancer4. They are, however, treated with much higher doses of immunosuppressive agents than patients with lupus. In the studies of Petterson et al.5, Abu-Shakra6 and Sultan et al.7, the use of cytotoxic agents was not related to the occurrence of malignancy. Our patient was treated only with corticosteroids. It may be that the disease itself confers an increased risk. Patients with SLE have defects in both their cellular and humoral immune systems.

The mechanisms of hematologic malignancies8 are thought to be related to the following:

  • Failure or dysregulation of apoptosis as a result of mutated genes in SLE (Fas ligand).

  • Accumulation of and mutations in B and T lymphocytes in the lymph nodes.

  • T-cell immunodeficiency, allowing Epstein-Barr virus (EBV)-infected B-cell proliferation.

  • Exposure to immunosuppressive medications (possible increased risk of EBV infection in patients with SLE)9.

Large multicenter studies are required to adequately address the risk of developing malignancies in large cohorts of patients with SLE and to address issues such as associated risk factors and additional confounding factors, such as deprivation and exposure to therapy. The chance of detection of malignancy may vary due to factors such as access to health services, which vary widely and are not uniformly available, and may therefore underestimate the risk of malignancy.

Conclusion

SLE has been associated with increased frequency of neoplasia, lymphoma, leukaemia and epithelial tumours. Hodgkin’s disease has been occasionally associated with SLE in adults. An awareness of the association of Hodgkin’s disease with SLE and the modes of presentation will help in the early diagnosis and clinical management of such patients.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 18 Oct 2012
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Dhaou BB, Boussema F, Aydi Z et al. Systemic lupus erythematosus and Hodgkin disease [version 1; peer review: 1 approved, 1 approved with reservations]. F1000Research 2012, 1:31 (https://doi.org/10.12688/f1000research.1-31.v1)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 1
VERSION 1
PUBLISHED 18 Oct 2012
Views
8
Cite
Reviewer Report 12 Nov 2012
Frederic Geissmann, Centre for Molecular and Cellular Biology of Inflammation, Kings College London, London, UK 
Approved with Reservations
VIEWS 8
The authors described a case of association of Hodgkin’s disease with systemic lupus erythematosus. This clinical report is interesting, if not novel, and reminds the clinician that persistent lymphadenopathy in SLE patients, can be due in some case to a
... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Geissmann F. Reviewer Report For: Systemic lupus erythematosus and Hodgkin disease [version 1; peer review: 1 approved, 1 approved with reservations]. F1000Research 2012, 1:31 (https://doi.org/10.5256/f1000research.206.r342)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Views
6
Cite
Reviewer Report 30 Oct 2012
Eoin McKinney, Department of Medicine and Cambridge Institute for Medical Research, Addenbrooke’s Hospital, University of Cambridge School of Clinical Medicine, Cambridge, UK 
Approved
VIEWS 6
I confirm that I have read this submission and believe that I have an ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
McKinney E. Reviewer Report For: Systemic lupus erythematosus and Hodgkin disease [version 1; peer review: 1 approved, 1 approved with reservations]. F1000Research 2012, 1:31 (https://doi.org/10.5256/f1000research.206.r341)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.

Comments on this article Comments (0)

Version 1
VERSION 1 PUBLISHED 18 Oct 2012
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.